Teladoc Health
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 weeks.
- Recent price momentum is +12.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 17.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 1.7% | Better than 33% |
| Free cash flow CAGR (3Y) | 102.5% | Better than 93% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 69.5% | Better than 82% |
| Operating margin | -6.5% | Better than 16% |
| Net margin | -7.9% | Better than 17% |
| Return on equity | -13.9% | Better than 18% |
| Return on invested capital | -7.8% | Better than 19% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 16.6% | Better than 95% |
| 6-month return | 13.4% | Better than 76% |
| 12-month return (ex latest month) | -8.9% | Better than 24% |
| Distance below 52-week high | 24.6% | Better than 51% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.8x | Better than 70% |
| Debt to assets | 36.4% | Better than 31% |
| Interest coverage | -10.9x | Better than 13% |
Analyst View C
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 33.3% | Better than 18% |
| Upside to average target | 26.7% | Better than 44% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.79
- Open
- 7.68
- Day range
- 7.40 - 7.88
- Avg price
- 7.56
- Volume
- 4.71M
- Turnover
- 35.57M
- Turnover ratei
- 2.60%
- Volume ratioi
- 1.21
- Amplitudei
- 6.10%
- 52-week rangei
- 4.40 - 9.89
Valuation
- P/Ei
- -6.54
- P/E (TTM)i
- -8.66
- P/Bi
- 1.05
- EPSi
- -1.14
- Book value / shi
- 7.10
- Net profit
- -207.81M
- Net assets
- 1.29B
Share structure
- Market cap
- 1.36B
- Float capi
- 1.35B
- Shares out
- 182.29M
- Float sharesi
- 181.07M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-07-01
24.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+4.98M net over the window
Short interest
- Shares short
- 32.19M
- % of floati
- 17.66%
- Days to coveri
- 5.65
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Teladoc Health (TDOC)?
Teladoc Health last traded at 7.45. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Teladoc Health's market cap?
About 1.36B.
What is the P/E ratio of Teladoc Health?
The trailing twelve-month P/E is -8.66. The Valuation tab shows it against the stock's own five-year range.
Does Teladoc Health pay a dividend?
Teladoc Health does not currently pay a regular dividend.
Is Teladoc Health a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 9.44, which implies 26.7% upside from the current price. This is not investment advice.
What is Teladoc Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Teladoc Health a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:44:00 · For reference only, not investment advice and not tailored to your situation.
Teladoc Health discussion 0 comments